vyvanse and glp-1 Update: is approved in the USA for BED. It’s not approved in Europe, where this study was conducted. , Can receptor agonists help with binge eating? This retrospective study says they GLP-1, Vyvanse & Addiction: Understanding

[88] In March 2026, the CHMP recommended granting a conditional marketing authorization for Kayshild (semaglutide), a GLP-1 receptor agonist for the treatment of non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with liver fibrosis, a serious disease where fat deposits accumulate in the liver causing inflammation

Between increased healthcare costs, decreased productivity, premature retirements, and rising death rates, its estimated that the global costs associated with obesity will reach USD 2.47 trillion in 2025

By increasing insulin production, regulating blood sugar and inducing a sense of fullness, these medications lead to significant weight loss

Many people are suing GLP-1 manufacturers because of side effects like gastroparesis and other serious disorders

Nevola R, Epifani R, Imbriani S et al (2023) GLP-1 receptor agonists in non-alcoholic fatty liver disease: current evidence and future perspectives